Federal Register / Vol. 81, No. 19 / Friday, January 29, 2016 / Notices 5015 

or delivered to a Medicaid patient. This 

review includes screening for potential 

drug therapy problems due to 

therapeutic duplication, drug-disease 

contraindications, drug-drug 

interactions, incorrect drug dosage or 

duration of drug treatment, drug-allergy 

interactions, and clinical abuse/misuse. 

Pharmacists must make a reasonable 

effort to obtain, record, and maintain 

Medicaid patient profiles. These profiles 

must reflect at least the patient’s name, 

address, telephone number, date of 

birth/age, gender, history, e.g., allergies, 

drug reactions, list of medications, and 

pharmacist’s comments relevant to the 

individual’s drug therapy. 

The State must conduct RetroDUR 

which provides for the ongoing periodic 

examination of claims data and other 

records in order to identify patterns of 

fraud, abuse, inappropriate or medically 

unnecessary care. Patterns or trends of 

drug therapy problems are identified 

and reviewed to determine the need for 

intervention activity with pharmacists 

and/or physicians. States may conduct 

interventions via telephone, 

correspondence, or face-to-face contact. 

Annual reports are submitted to CMS 

for the purposes of monitoring 

compliance and evaluating the progress 

of States’ DUR programs. The 

information submitted by States is 

reviewed and results are compiled by 

CMS in a format intended to provide 

information, comparisons and trends 

related to States’ experiences with DUR. 

The States benefit from the information 

and may enhance their programs each 

year based on State reported innovative 

practices that are compiled by CMS 

from the DUR annual reports. Form 

Number: CMS–R–153 (OMB Control 

Number 0938–0659); Frequency: Yearly, 

quarterly, and occasionally; Affected 

Public: State, Local, or Tribal 

Governments; Number of Respondents: 

51; Total Annual Responses: 510; Total 

Annual Hours: 20,808. (For policy 

questions regarding this collection 

contact Renee Hilliard at 410–786– 

2991). 

Dated: January 25, 2016. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2016–01688 Filed 1–28–16; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifiers: CMS–10519] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 

(PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, and to allow 

a second opportunity for public 

comment on the notice. Interested 

persons are invited to send comments 

regarding the burden estimate or any 

other aspect of this collection of 

information, including any of the 

following subjects: (1) The necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions; (2) the accuracy 

of the estimated burden; (3) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; and 

(4) the use of automated collection 

techniques or other forms of information 

technology to minimize the information 

collection burden. 

DATES: Comments on the collection(s) of 

information must be received by the 

OMB desk officer by February 29, 2016. 

ADDRESSES: When commenting on the 

proposed information collections, 

please reference the document identifier 

or OMB control number. To be assured 

consideration, comments and 

recommendations must be received by 

the OMB desk officer via one of the 

following transmissions: OMB, Office of 

Information and Regulatory Affairs, 

Attention: CMS Desk Officer, Fax 

Number: (202) 395–5806 OR, Email: 

OIRA_submission@omb.eop.gov. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, you may make your request 

using one of following: 

1. Access CMS’ Web site address at 

http://www.cms.hhs.gov/ 

PaperworkReductionActof1995. 

2. Email your request, including your 

address, phone number, OMB number, 

and CMS document identifier, to 

Paperwork@cms.hhs.gov. 

3. Call the Reports Clearance Office at 

(410) 786–1326. 

FOR FURTHER INFORMATION CONTACT: 

Reports Clearance Office at (410) 786– 

1326. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. The term ‘‘collection of 

information’’ is defined in 44 U.S.C. 

3502(3) and 5 CFR 1320.3(c) and 

includes agency requests or 

requirements that members of the public 

submit reports, keep records, or provide 

information to a third party. Section 

3506(c)(2)(A) of the PRA (44 U.S.C. 

3506(c)(2)(A)) requires federal agencies 

to publish a 30-day notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension or 

reinstatement of an existing collection 

of information, before submitting the 

collection to OMB for approval. To 

comply with this requirement, CMS is 

publishing this notice that summarizes 

the following proposed collection(s) of 

information for public comment: 

1. Type of Information Collection 

Request: Revision of a currently 

approved collection; Title of 

Information Collection: Physician 

Quality Reporting System (PQRS) and 

the Electronic Prescribing Incentive 

(eRx) Program Data Assessment, 

Accuracy and Improper Payments 

Identification Support; Use: The 

incentive and reporting programs have 

data integrity issues, such as rejected 

and improper payments. This four year 

project will evaluate incentive payment 

information for accuracy and identify 

improper payments, with the goal of 

recovering these payments. 

Additionally, based on the project’s 

results, recommendations will be made 

so that we can avoid future data 

integrity issues. 

Data submission, processing, and 

reporting will be analyzed for potential 

errors, inconsistencies, and gaps that are 

related to data handling, program 

requirements, and clinical quality 

measure specifications of PQRS and eRx 

program. Surveys of Group Practices, 

Registries, and Data Submission 

Vendors (DSVs) will be conducted in 

order to evaluate the PQRS and eRx 

Incentive Program. Follow-up 

interviews will occur with a small 

number of respondents. Form Number: 

CMS–10519 (OMB control number: 

0938–1255); Frequency: Annually; 

Affected Public: Business or other forprofits; Number of Respondents: 115; 


jstallworth on DSK7TPTVN1PROD with NOTICES
5016 Federal Register / Vol. 81, No. 19 / Friday, January 29, 2016 / Notices 

Total Annual Responses: 115 Total 

Annual Hours: 173. (For policy 

questions regarding this collection 

contact Timothy Jackson at 410–786– 

4006.) 

Dated: January 25, 2016. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2016–01689 Filed 1–28–16; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; ADNI–3. 

Date: February 24, 2016. 

Time: 12:30 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, Suite 2C212, 7201 

Wisconsin Avenue, Bethesda, MD 20892. 

Contact Person: Alexander Parsadanian, 

Ph.D., Scientific Review Officer, National 

Institute on Aging, Gateway Building 2C212, 

7201 Wisconsin Avenue, Bethesda, MD 

20892, 301–496–9666, parsadaniana@

nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: January 25, 2016. 

Melanie J. Gray, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2016–01697 Filed 1–28–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI 

Omnibus SEP–8. 

Date: March 11, 2016. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel and 

Conference Center, 5701 Marinelli Road, 

Room Brookside A&B, North Bethesda, MD 

20852. 

Contact Person: Jennifer C. Schiltz, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W634, Rockville, MD 

20850, 240–276–5864, jennifer.schiltz@

nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI 

Omnibus SEP–11A. 

Date: March 21, 2016. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W602 Rockville, MD 20850, (Telephone 

Conference Call). 

Contact Person: Delia Tang, MD, Scientific 

Review Officer, Research Programs, Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W602, Bethesda, MD 

20892, 240–276–6456, tangd@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: January 25, 2016. 

Melanie J. Gray, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2016–01696 Filed 1–28–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR14–008: 

Psychiatric Disease, Genetics and RDoC 

Framework. 

Date: February 22, 2016. 

Time: 1:30 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Julius Cinque, MS, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5186, 

MSC 7846, Bethesda, MD 20892, (301) 435– 

1252, cinquej@csr.nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience Integrated Review 

Group; Clinical Neuroplasticity and 

Neurotransmitters Study Section. 

Date: February 25–26, 2016. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Argonaut Hotel, 495 Jefferson Street, 

San Francisco, CA 94109. 

Contact Person: Suzan Nadi, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5217B, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1259, nadis@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Fellowship: 

Immunology. 

Date: February 25–26, 2016. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 


jstallworth on DSK7TPTVN1PROD with NOTICES